These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 38783925)

  • 1. Breaking barriers: The potential of nanosystems in antituberculosis therapy.
    Carnero Canales CS; Marquez Cazorla JI; Marquez Cazorla RM; Roque-Borda CA; Polinário G; Figueroa Banda RA; Sábio RM; Chorilli M; Santos HA; Pavan FR
    Bioact Mater; 2024 Sep; 39():106-134. PubMed ID: 38783925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.
    Suman SK; Chandrasekaran N; Priya Doss CG
    Clin Microbiol Rev; 2023 Dec; 36(4):e0008823. PubMed ID: 38032192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis.
    Man DK; Chow MY; Casettari L; Gonzalez-Juarrero M; Lam JK
    Adv Drug Deliv Rev; 2016 Jul; 102():21-32. PubMed ID: 27108702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced drug delivery and therapeutic strategies for tuberculosis treatment.
    Nair A; Greeny A; Nandan A; Sah RK; Jose A; Dyawanapelly S; Junnuthula V; K V A; Sadanandan P
    J Nanobiotechnology; 2023 Nov; 21(1):414. PubMed ID: 37946240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review.
    Kiran D; Basaraba RJ
    Front Cell Infect Microbiol; 2021; 11():624607. PubMed ID: 33718271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
    Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
    Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.
    Dastidar DG; Roy A; Ghosh G; Mandal S
    Curr Drug Deliv; 2024 Apr; ():. PubMed ID: 38693736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
    Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
    Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review.
    R PA; Anbarasu A
    Probiotics Antimicrob Proteins; 2023 Dec; 15(6):1539-1566. PubMed ID: 36576687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multilayer precision-based screening of potential inhibitors targeting Mycobacterium tuberculosis acetate kinase using in silico approaches.
    Subramaniyan S; Nagarajan H; Vetrivel U; Jeyaraman J
    Comput Biol Chem; 2023 Dec; 107():107942. PubMed ID: 37673012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
    Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
    Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Rewiring of
    Singha B; Murmu S; Nair T; Rawat RS; Sharma AK; Soni V
    Metabolites; 2024 Jan; 14(1):. PubMed ID: 38248866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising Antimycobacterial Activities of Flavonoids against
    Rabaan AA; Alhumaid S; Albayat H; Alsaeed M; Alofi FS; Al-Howaidi MH; Turkistani SA; Alhajri SM; Alahmed HE; Alzahrani AB; Mashraqi MM; Alwarthan S; Alhajri M; Alshahrani FS; Almuthree SA; Alsubki RA; Abuzaid AA; Alfaresi M; Al Fares MA; Mutair AA
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014572
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.